🇺🇸 FDA
Pipeline program

XEN496

XPF-009-302

Phase 3 small_molecule terminated

Quick answer

XEN496 for Epilepsy is a Phase 3 program (small_molecule) at Xenon Pharmaceuticals with 2 ClinicalTrials.gov record(s).

Program details

Company
Xenon Pharmaceuticals
Indication
Epilepsy
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials